-
1.发明公开USE OF IMMUNOREGULATORY ANTIBODIES IN THE TREATMENT OF NEOPLASTIC DISORDERS 审中-公开抗CD80和抗CD20抗体的用于肿瘤性疾病治疗中使用
公开(公告)号：EP1372724A2
公开(公告)日：2004-01-02
申请号：EP02709219.6
申请日：2002-01-31
发明人： HARIHARAN, Kandasamy , HANNA, Nabil
IPC分类号： A61K45/00 , A61K45/06 , A61K39/395 , A61P35/00 , A61P35/02
CPC分类号： C07K16/2887 , A61K39/39541 , A61K2039/505 , A61K2039/507 , C07K16/2827 , C07K16/2851 , C07K16/2875 , C07K16/2878 , C07K2317/24 , C07K2317/732 , C07K2317/734 , A61K2300/00
摘要： A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
-
公开(公告)号：EP1373321A2
公开(公告)日：2004-01-02
申请号：EP02706010.2
申请日：2002-01-29
发明人： BRASLAWSKY, Gary, R. , HANNA, Nabil , CHINN, Paul
CPC分类号： C07K16/2887 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6901 , A61K51/1027 , A61K51/1045 , A61K51/1072 , A61K2039/505 , C07K16/00 , C07K16/30 , C07K2317/24 , C07K2317/52 , C07K2319/00 , C12N15/85 , C12P21/02
摘要： Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.
-
3.发明公开COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA 审中-公开作者抗细胞因子抗体或拮抗剂和抗CD20用于治疗B细胞淋巴瘤结合使用
公开(公告)号：EP1283722A1
公开(公告)日：2003-02-19
申请号：EP01964666.0
申请日：2001-04-02
发明人： HANNA, Nabil
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/244 , A61K38/00 , A61K39/39541 , A61K39/3955 , A61K2039/505 , C07K16/24 , A61K2300/00
摘要： The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUSAN®.
-
4.发明公开
公开(公告)号：EP1370292A1
公开(公告)日：2003-12-17
申请号：EP02704280.3
申请日：2002-01-31
IPC分类号： A61K45/00 , A61K45/06 , A61K39/395 , A61P35/00 , A61P35/02
CPC分类号： C07K16/2896 , A61K47/6849 , A61K2039/505 , C07K16/2827 , C07K16/2851 , C07K16/2875 , C07K2317/24 , C07K2317/732
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
-
5.发明公开NON-AGONISTIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF 审中-公开NICHTAGONISTISCHE抗体的人gp39的，组合物和用途
公开(公告)号：EP1299542A2
公开(公告)日：2003-04-09
申请号：EP01941911.8
申请日：2001-06-06
发明人： ANDERSON, Darrell, R. , PAN, Li, Zhen , HANNA, Nabil , RASTETTER, William, H. , KLOETZER, William, S.
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24
摘要： The present invention is directed to antibodies which bind human gp39, are antagonistic of the CD40/CD40L interaction, but are non-agonistic of T-cell activation. The present invention is further directed to the use of these antibodies as therapeutic agents. These antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
-
6.发明公开THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA 失效限制了B细胞淋巴瘤治疗人B淋巴细胞分化抗原的嵌合和标记的抗体治疗用途。
公开(公告)号：EP0669836A1
公开(公告)日：1995-09-06
申请号：EP94901444.0
申请日：1993-11-12
发明人： ANDERSON, Darrell, R. , RASTETTER, William, H. , HANNA, Nabil , LEONARD, John, E. , NEWMAN, Roland, A. , REFF, Mitchell, E.
IPC分类号： C12N15 , A61K31 , A61K39 , A61K45 , A61K47 , A61K51 , A61P35 , C07K16 , C12N5 , C12P21 , G01N33 , A61K38 , C12R1
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
-
7.发明公开COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION 审中-公开联合疗法用于自身免疫性疾病的治疗中使用的组合B-CELL除去剂/免疫调节ANTIBODIES
公开(公告)号：EP1328320A2
公开(公告)日：2003-07-23
申请号：EP01971112.6
申请日：2001-09-18
发明人： HANNA, Nabil
IPC分类号： A61P37/00 , A61K39/395 , A61K47/48 , A61K51/10
摘要： The present invention concerns treatment of autoimmune diseases with the combination of an immunoregulatory antibody, e.g. and anti-B7.1 or anti-B7.2 or anti-CD40L antibody and at least one B cell antibody, such as CD19, CD20, CD22, CD23, or CD37, wherein such antibodies may be administered separately, or in combination, and in either, over prolonged periods of time.
-
8.发明公开TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY 审中-公开FOR使用针对CD40L B细胞恶性疾病的处理方法靶向抗体针对CD20用靶向抗体和/或其化疗药物放射治疗
公开(公告)号：EP1229935A1
公开(公告)日：2002-08-14
申请号：EP00986212.9
申请日：2000-11-06
发明人： HANNA, Nabil , HARIHARAN, Kandasamy
IPC分类号： A61K39/395 , A61K51/10 , A61P35/02
CPC分类号： C07K16/2887 , A61K39/39533 , A61K51/1027 , A61K2039/505 , A61K2039/507 , C07K16/2827 , C07K16/2851 , C07K16/2875 , C07K2317/24 , A61K39/395 , A61K33/24 , A61K31/00 , A61K2300/00
摘要： The invention discloses compositions, combination therapies and methods of treating B-cell lymphomas and leukemias, as well as other CD40+ malignancies. The primary active agent of the composition is an anti-CD40L antibody or other CD40L antagonist that inhibits CD40-CD40L interaction. Compositions may additionally contain or utilize any one or more of the following in combination for the treatment of said disease: anti-CD20 antibodies, chemotherapeutic agents, chemotherapy cocktails, and radiotherapy.
-
公开(公告)号：EP1157042A1
公开(公告)日：2001-11-28
申请号：EP00913253.1
申请日：2000-01-28
发明人： BRASLAWSKY, Gary, Ronald , HANNA, Nabil , HARIHARAN, Kandasamy , LABARRE, Michael, J. , HUYNH, Tri, B.
CPC分类号： C07K16/2887 , A61K47/6835 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/31 , C07K2317/734
摘要： The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through a reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.
-
10.发明公开SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS 审中-公开协同组合物和方法用于治疗癌症或肿瘤样生长及恢复或起搏造血
公开(公告)号：EP1015031A1
公开(公告)日：2000-07-05
申请号：EP98949313.5
申请日：1998-09-17
CPC分类号： A61K39/00 , A61K9/1075 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K39/39558 , A61K2039/505 , A61K2039/55516 , A61K2039/55522 , A61K2039/55555 , A61K2039/55566 , A61K2039/57 , A61K2039/585 , C07K16/22 , C07K2317/76 , C12N2710/20034 , Y02A50/412 , Y02A50/464 , A61K2300/00
摘要： The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.017 秒)
